JP6474804B2 - アザベンゾイミダゾール誘導体 - Google Patents
アザベンゾイミダゾール誘導体 Download PDFInfo
- Publication number
- JP6474804B2 JP6474804B2 JP2016527342A JP2016527342A JP6474804B2 JP 6474804 B2 JP6474804 B2 JP 6474804B2 JP 2016527342 A JP2016527342 A JP 2016527342A JP 2016527342 A JP2016527342 A JP 2016527342A JP 6474804 B2 JP6474804 B2 JP 6474804B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- imidazo
- chloro
- phenyl
- yloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- UCCUXODGPMAHRL-UHFFFAOYSA-N Brc(cc1)ccc1I Chemical compound Brc(cc1)ccc1I UCCUXODGPMAHRL-UHFFFAOYSA-N 0.000 description 1
- WURIZMVXLWUAEN-UHFFFAOYSA-N CC(C)(C)OC(NC(CC1)CCN1c(cc1)ccc1Br)=O Chemical compound CC(C)(C)OC(NC(CC1)CCN1c(cc1)ccc1Br)=O WURIZMVXLWUAEN-UHFFFAOYSA-N 0.000 description 1
- CKXZPVPIDOJLLM-UHFFFAOYSA-N CC(C)(C)OC(NC1CCNCC1)=O Chemical compound CC(C)(C)OC(NC1CCNCC1)=O CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 1
- PCJQIDWFGLHJAG-XHKMEICASA-O CC(C)(C)[SH+]OC(CO[C@@H]12)[C@H]1OC[C@H]2Oc1nc2cc(Cl)c(-c3ccc([C@H](CC4)CC[C@H]4OC(N4CCOCC4)=O)cc3)nc2[n]1COCC[Si+](C)(C)C Chemical compound CC(C)(C)[SH+]OC(CO[C@@H]12)[C@H]1OC[C@H]2Oc1nc2cc(Cl)c(-c3ccc([C@H](CC4)CC[C@H]4OC(N4CCOCC4)=O)cc3)nc2[n]1COCC[Si+](C)(C)C PCJQIDWFGLHJAG-XHKMEICASA-O 0.000 description 1
- SSZQDJZDPYIHSN-OXCWUASISA-O CC(C)(C)[SH+]O[C@H]1[C@H]2OC[C@@H](COc3nc4cc(Cl)c(-c5ccc([C@H](CC6)CC[C@H]6O)cc5)nc4[n]3COCC[Si+](C)(C)C)[C@H]2OC1 Chemical compound CC(C)(C)[SH+]O[C@H]1[C@H]2OC[C@@H](COc3nc4cc(Cl)c(-c5ccc([C@H](CC6)CC[C@H]6O)cc5)nc4[n]3COCC[Si+](C)(C)C)[C@H]2OC1 SSZQDJZDPYIHSN-OXCWUASISA-O 0.000 description 1
- WOBBBCGQZGWXDO-XCOWOKAYSA-N CC(C)NC(O[C@H](CC1)CC[C@@H]1c(cc1)ccc1-c(nc1[nH]c(O[C@H](CO[C@@H]23)[C@H]2OC[C@H]3O)nc1c1)c1Cl)=O Chemical compound CC(C)NC(O[C@H](CC1)CC[C@@H]1c(cc1)ccc1-c(nc1[nH]c(O[C@H](CO[C@@H]23)[C@H]2OC[C@H]3O)nc1c1)c1Cl)=O WOBBBCGQZGWXDO-XCOWOKAYSA-N 0.000 description 1
- ODWJAQMJCRYSGZ-UHFFFAOYSA-N CC1(C)OB(c2ccc(C(CC3)CCC3O)cc2)OC1(C)C Chemical compound CC1(C)OB(c2ccc(C(CC3)CCC3O)cc2)OC1(C)C ODWJAQMJCRYSGZ-UHFFFAOYSA-N 0.000 description 1
- LLHVZXDLQRKTSP-UHFFFAOYSA-N CCOC(NC(CC1)CCN1c(cc1)ccc1Br)=O Chemical compound CCOC(NC(CC1)CCN1c(cc1)ccc1Br)=O LLHVZXDLQRKTSP-UHFFFAOYSA-N 0.000 description 1
- RSYVPKBQWMLGRX-UHFFFAOYSA-N CCOC(NC(CC1)CCN1c1ccc(B2OC(C)(C)C(C)(C)O2)cc1)=O Chemical compound CCOC(NC(CC1)CCN1c1ccc(B2OC(C)(C)C(C)(C)O2)cc1)=O RSYVPKBQWMLGRX-UHFFFAOYSA-N 0.000 description 1
- JUHJMRCPZRWQAM-DBRKOABJSA-N C[C@H](CO[C@@H]12)[C@H]1OC[C@H]2O Chemical compound C[C@H](CO[C@@H]12)[C@H]1OC[C@H]2O JUHJMRCPZRWQAM-DBRKOABJSA-N 0.000 description 1
- BVDDMNLGRSKWBY-KBUPBQIOSA-N C[Si+](C)(C)CCOC[n](c1n2)c(O[C@H](CO[C@@H]34)[C@H]3OC[C@H]4O)nc1cc(Cl)c2I Chemical compound C[Si+](C)(C)CCOC[n](c1n2)c(O[C@H](CO[C@@H]34)[C@H]3OC[C@H]4O)nc1cc(Cl)c2I BVDDMNLGRSKWBY-KBUPBQIOSA-N 0.000 description 1
- XDGZMSJRQSPGOV-UGESXGAOSA-N C[Si+](C)(C)CCOC[n]1c(O[C@H](CO[C@@H]23)[C@H]2OC[C@H]3O)nc2cc(Cl)c(-c(cc3)ccc3Br)nc12 Chemical compound C[Si+](C)(C)CCOC[n]1c(O[C@H](CO[C@@H]23)[C@H]2OC[C@H]3O)nc2cc(Cl)c(-c(cc3)ccc3Br)nc12 XDGZMSJRQSPGOV-UGESXGAOSA-N 0.000 description 1
- IZOLRQHKQBZZLK-UHFFFAOYSA-N C[Si](C)(C)CCOC[n]1c(O)nc2cc(Cl)c(-c(cc3)ccc3Br)nc12 Chemical compound C[Si](C)(C)CCOC[n]1c(O)nc2cc(Cl)c(-c(cc3)ccc3Br)nc12 IZOLRQHKQBZZLK-UHFFFAOYSA-N 0.000 description 1
- LJRVMCJVBJLUMQ-NFXXYORJSA-N C[Si](C)(C)CCOC[n]1c(OC[C@H](CO[C@@H]23)[C@H]2OC[C@H]3O)nc2cc(Cl)c(-c(cc3)ccc3N(CC3)CCC3OC(N3CCOCC3)=O)nc12 Chemical compound C[Si](C)(C)CCOC[n]1c(OC[C@H](CO[C@@H]23)[C@H]2OC[C@H]3O)nc2cc(Cl)c(-c(cc3)ccc3N(CC3)CCC3OC(N3CCOCC3)=O)nc12 LJRVMCJVBJLUMQ-NFXXYORJSA-N 0.000 description 1
- MSRULTHBAHWIAW-UHFFFAOYSA-N NC(CC1)CCN1c(cc1)ccc1Br Chemical compound NC(CC1)CCN1c(cc1)ccc1Br MSRULTHBAHWIAW-UHFFFAOYSA-N 0.000 description 1
- ULFBIAWHNKDNHR-UHFFFAOYSA-N O=C(N1CCOCC1)OC1CCNCC1 Chemical compound O=C(N1CCOCC1)OC1CCNCC1 ULFBIAWHNKDNHR-UHFFFAOYSA-N 0.000 description 1
- LWSZINXZJNQBQR-UHFFFAOYSA-N O=C(c(cccc1)c1F)OC(CC1)CCC1c(cc1)ccc1Br Chemical compound O=C(c(cccc1)c1F)OC(CC1)CCC1c(cc1)ccc1Br LWSZINXZJNQBQR-UHFFFAOYSA-N 0.000 description 1
- QBLFZIBJXUQVRF-UHFFFAOYSA-N OB(c(cc1)ccc1Br)O Chemical compound OB(c(cc1)ccc1Br)O QBLFZIBJXUQVRF-UHFFFAOYSA-N 0.000 description 1
- VGYAAWYHVAAJNX-UMSPYCQHSA-N O[C@H](CC1)CC[C@@H]1c(cc1)ccc1Br Chemical compound O[C@H](CC1)CC[C@@H]1c(cc1)ccc1Br VGYAAWYHVAAJNX-UMSPYCQHSA-N 0.000 description 1
- VGYAAWYHVAAJNX-KLPPZKSPSA-N O[C@H](CC1)CC[C@H]1c(cc1)ccc1Br Chemical compound O[C@H](CC1)CC[C@H]1c(cc1)ccc1Br VGYAAWYHVAAJNX-KLPPZKSPSA-N 0.000 description 1
- ZUPSWAVAKGLOSO-PXQNOSEYSA-N O[C@H](CO[C@@H]12)[C@H]1OC[C@H]2Oc1nc2cc(Cl)c(-c3ccc([C@H](CC4)CC[C@@H]4OC(N4CCCC4)=O)cc3)nc2[nH]1 Chemical compound O[C@H](CO[C@@H]12)[C@H]1OC[C@H]2Oc1nc2cc(Cl)c(-c3ccc([C@H](CC4)CC[C@@H]4OC(N4CCCC4)=O)cc3)nc2[nH]1 ZUPSWAVAKGLOSO-PXQNOSEYSA-N 0.000 description 1
- WGQCDRVRPGAGLL-XIEJWFEFSA-N O[C@H](CO[C@@H]12)[C@H]1OC[C@H]2Oc1nc2cc(Cl)c(-c3ccc([C@H](CC4)CC[C@H]4OC(N4CCOCC4)=O)cc3)nc2[nH]1 Chemical compound O[C@H](CO[C@@H]12)[C@H]1OC[C@H]2Oc1nc2cc(Cl)c(-c3ccc([C@H](CC4)CC[C@H]4OC(N4CCOCC4)=O)cc3)nc2[nH]1 WGQCDRVRPGAGLL-XIEJWFEFSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13191195.0 | 2013-10-31 | ||
| EP13191195 | 2013-10-31 | ||
| PCT/EP2014/072959 WO2015063011A1 (en) | 2013-10-31 | 2014-10-27 | Azabenzimidazole derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016535049A JP2016535049A (ja) | 2016-11-10 |
| JP2016535049A5 JP2016535049A5 (cg-RX-API-DMAC10.html) | 2017-12-14 |
| JP6474804B2 true JP6474804B2 (ja) | 2019-02-27 |
Family
ID=49488531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016527342A Active JP6474804B2 (ja) | 2013-10-31 | 2014-10-27 | アザベンゾイミダゾール誘導体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9187477B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3063148B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6474804B2 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2015063011A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107108605A (zh) | 2014-08-27 | 2017-08-29 | 盐野义制药株式会社 | 具有ampk活化作用的氮杂吲哚衍生物 |
| CN107108521A (zh) | 2014-10-28 | 2017-08-29 | 盐野义制药株式会社 | 具有ampk活化作用的杂环衍生物 |
| WO2017146186A1 (ja) | 2016-02-26 | 2017-08-31 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有する５－フェニルアザインドール誘導体 |
| EP3459949A4 (en) * | 2016-05-20 | 2020-04-08 | Shionogi & Co., Ltd | 5-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE AND 5-SUBSTITUTED AZABENZIMIDAZOLE DERIVATIVE WITH AMPK ACTIVATION EFFECT |
| MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2826649C (en) * | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| MX2014000452A (es) * | 2011-07-15 | 2014-03-21 | Shionogi & Co | Derivados de azabencimiazol que tiene actividad activadora de la proteina cinasa activada monofosfato de denosina (ampk). |
| EP2888006B1 (en) * | 2012-08-22 | 2019-04-24 | Merck Sharp & Dohme Corp. | Novel azabenzimidazole tetrahydropyran derivatives useful as ampk activators |
-
2014
- 2014-10-27 JP JP2016527342A patent/JP6474804B2/ja active Active
- 2014-10-27 WO PCT/EP2014/072959 patent/WO2015063011A1/en not_active Ceased
- 2014-10-27 EP EP14789561.9A patent/EP3063148B1/en active Active
- 2014-10-28 US US14/525,950 patent/US9187477B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016535049A (ja) | 2016-11-10 |
| EP3063148A1 (en) | 2016-09-07 |
| EP3063148B1 (en) | 2020-04-29 |
| US20150119393A1 (en) | 2015-04-30 |
| US9187477B2 (en) | 2015-11-17 |
| WO2015063011A1 (en) | 2015-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6588966B2 (ja) | Ａｍｐタンパク質キナーゼ作動薬としてのアザベンゾイミダゾール誘導体 | |
| CN105377857B (zh) | 新颖氮杂苯并咪唑衍生物 | |
| EP2953681B1 (en) | New indanyloxydihydrobenzofuranylacetic acids | |
| US11931350B2 (en) | Opioid receptor ligands and methods of using and making same | |
| EP3573952B1 (en) | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceuticalcompositions and uses thereof | |
| JP2016535049A (ja) | アザベンゾイミダゾール誘導体 | |
| JP6612881B2 (ja) | 新規なアザベンゾイミダゾール誘導体 | |
| JP6612880B2 (ja) | Ａｍｐ活性化タンパク質キナーゼのアゴニストとしての新規アザベンゾイミダゾール誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171026 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20171026 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171026 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180717 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180712 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180927 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190124 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190130 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6474804 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |